Home/Pipeline/SAGE-689

SAGE-689

Not Disclosed

Phase 1Paused

Key Facts

Indication

Not Disclosed

Phase

Phase 1

Status

Paused

Company

Sage Therapeutics

About Sage Therapeutics

Sage Therapeutics' mission is to pioneer life-changing brain health medicines, achieving a landmark success with the first FDA-approved drug for postpartum depression, ZULRESSO. The company's strategy is built on a proprietary platform targeting GABA and NMDA receptors to develop rapid-onset therapies for mood and neurological disorders. While facing commercial challenges, Sage is advancing a promising pipeline and has implemented strategic partnerships and cost reductions to extend its runway and focus on high-value programs.

View full company profile

Therapeutic Areas

Neuroscience Neuropsychiatry

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
SRSD101	Sirius Therapeutics	Phase 1	Active